Lipid degradation promotes prostate cancer cell survival. by Itkonen, H, Brown, M, Urbanucci, A, Tredwell, G, Ho Lau, C, Barfeld, S, Hart, C, Guldvik, I, Takhar, M, Heemers, H, Erho, N, Bloch, K, Davicioni, E, Derua, R, Waelkens, E, Mohler, J, Clarke, N, Swinnen, J, Keun, H, Rekvig, O, Mills, I

ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer by Centenera, MM, Scott, JS, Machiels, J, Nassar, ZD, Miller, DC, Zininos, I, Dehairs, J, Burvenich, IJG, Zadra, G, Chetta, P, Bango, C, Evergren, E, Ryan, NK, Gillis, JL, Mah, CY, Tieu, T, Hanson, AR, Carelli, R, Bloch, K, Panagopoulos, V, Waelkens, E, Derua, R, Williams, ED, Evdokioou, A, Cifuentes-Rius, A, Voelcker, NH, Mills, IG, Tilley, WD, Scott, AM, Loda, M, Selth, LA, Swinnen, JV, Butler, LM

Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity by Vriens, K, Christen, S, Parik, S, Broekaert, D, Yoshinaga, K, Talebi, A, Dehairs, J, Escalona-Noguero, C, Schmieder, R, Cornfield, T, Charlton, C, Romero-Pérez, L, Rossi, M, Rinaldi, G, Orth, M, Boon, R, Kerstens, A, Kwan, S, Faubert, B, Méndez-Lucas, A, Kopitz, C, Chen, T, Fernandez-Garcia, J, Duarte, J, Schmitz, A, Steigemann, P, Najimi, M, Hägebarth, A, Van Ginderachter, J, Sokal, E, Gotoh, N, Wong, K, Verfaillie, C, Derua, R, Munck, S, Yuneva, M, Beretta, L, Deberardinis, R, Swinnen, J, Hodson, L, Cassiman, D, Verslype, C, Christian, S, Grünewald, S, Grünewald, T, Fendt, S